Similar companies
| Company | Revenue | |
|---|---|---|
 |
Clearmind Medicine Common SharesCMND |
0 0% |
 |
enGenesENGN |
0 0% |
Income Statement (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Gross Profit | -760,000 | 0.3% |
| Cost of Revenue | 760,000 | 0.6% |
| Operating expense | 960,000 | 63.8% |
| Net Income | -970,000 | 63.4% |
| EBITDA | -960,000 | 63.6% |
Balance Sheet (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Total Assets | 1.7M | 113.4% |
| Total Liabilities | 2.9M | 36.9% |
| Shares Outstanding | 860,000 | 87% |
Cash Flow (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Cash from operations | -1.1M | 48% |
| Cash from investing | -90,000 | 0% |
| Cash from financing | 2M | 7.1% |
EPS
Financial Highlights for Alzamend Neuro in Q3 '24
Gross Profit stood at -760,000, marking a -0.3% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 760,000, a 0.6% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 960,000, showing a -63.8% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -970,000, showing a 63.4% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -960,000, showing a 63.6% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
Alzamend Neuro faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. An increase in the cost of revenue, higher than the revenue growth, suggests potential margin pressures.
